⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CYTK News
Cytokinetics Inc.
Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales
globenewswire.com
CYTK
Congestive Heart Failure Market to Register Immense Growth at a CAGR of 8% During the Forecast Period (2026-2036) | DelveInsight
prnewswire.com
CYTK
NVO
BCDA
AZN
BMY
LLY
MESO
ASMB
LXRX
VTRS
AMGN
IRWD
NVS
MRK
Cytokinetics to Announce Second Quarter Results on August 6, 2026
globenewswire.com
CYTK
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CYTK
Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026
globenewswire.com
CYTK
Imbria Pharmaceuticals Receives FDA Orphan Drug Designation for Ninerafaxstat for Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
globenewswire.com
CYTK
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CYTK
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program
globenewswire.com
CYTK
Cytokinetics bringt MYQORZO® (aficamten) in der Europäischen Union auf den Markt; der erste kommerzielle Vertrieb erfolgt in Deutschland
globenewswire.com
CYTK
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany
globenewswire.com
CYTK